Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,619 across all filing types
Latest filing 2022-10-17 Capital/Financing Update
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Trading Halt 2 pages 383.5KB
Capital/Financing Update Classification · 95% confidence The document is a market announcement from Pharmaxis Ltd regarding a trading halt requested under ASX Listing Rule 17.1. The halt is pending an announcement about the outcome of a capital raising via placement of shares. The document does not contain financial statements or detailed financial data but is an announcement about a capital raising event and trading halt. This fits the category of Capital/Financing Update (CAP) as it relates to fundraising activities and capital structure changes.
2022-10-17 English
PXS Releases Promising Interim Data from Skin Scarring Study 3 pages 182.6KB
Interim / Quarterly Report Classification · 95% confidence The document is a media release dated 26 September 2022 from Pharmaxis Ltd announcing interim data from a clinical trial (SOLARIA2) of their drug PXS-6302 for skin scarring. It discusses preliminary clinical results from 8 patients, ongoing recruitment, and expected final results in H1 2023. The document also references pre-clinical data published in Nature Communications and mentions an upcoming investor briefing. The content focuses on clinical trial interim data and updates rather than full financial results or comprehensive financial statements. It is not an earnings release since it does not present financial results, nor is it an annual or interim report. It is not a regulatory filing or certification. The document is a detailed announcement of interim clinical data, which fits best under the category of Interim / Quarterly Report (IR) because it provides substantive data and analysis for a period shorter than a full fiscal year, specifically interim clinical trial results. The document length (over 10,000 characters) and detailed data support this classification rather than a brief announcement or investor presentation. Therefore, the most appropriate classification is IR with high confidence. Q3 2022
2022-09-25 English
Investor Presentation Interim Data from Skin Scarring Study 9 pages 1.1MB
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation | 26 September 2022' and contains detailed information about Pharmaxis' clinical stage drug development programs, pipeline assets, clinical trial designs, anticipated news flow, and corporate strategy. It includes forward-looking statements, executive summary, clinical trial data, and commercial opportunities. The content is structured as a presentation aimed at investors, focusing on financial and strategic information rather than a formal regulatory filing or financial report. There is no indication that this is an annual report, earnings release, or regulatory filing. The length (over 10,000 characters) and detailed content support that this is the actual presentation document, not just an announcement of a report. Therefore, the document fits the definition of an Investor Presentation (IP).
2022-09-25 English
Date of Virtual AGM and Date for Director Nominations 1
AGM Information Classification · 95% confidence The document is a short announcement dated 13 September 2022 from Pharmaxis Ltd addressed to the Australian Securities Exchange. It informs about the date of the 2022 Annual General Meeting (AGM) to be held virtually on 15 November 2022 and the closing date for director nominations. There is no detailed report, financial data, or presentation content included. The document serves as a notification about the upcoming AGM and related procedural information, not the AGM materials themselves. Given the short length (1028 characters) and the nature of the content, this fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or announcements related to the AGM event.
2022-09-12 English
Investor presentation 16 pages 1.1MB
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation' and dated 06 September 2022. It contains detailed information about the company's clinical stage drug development programs, pipeline assets, clinical trials, scientific leadership, market opportunities, and strategic initiatives. The content is structured as a presentation with forward-looking statements, executive summary, scientific and clinical data, and commercial opportunities. There is no indication that this is a regulatory filing, earnings release, or annual report. The length is substantial (15,000 characters), consistent with a detailed presentation rather than a brief announcement or certification. Therefore, the document fits the definition of an Investor Presentation (IP).
2022-09-05 English
PXS to Receive Stg2.9m from Parkinsons UK for New Trial 4 pages 203.8KB
Capital/Financing Update Classification · 95% confidence The document is a media release announcing a funding agreement and upcoming clinical trial for a drug candidate by Pharmaxis. It details the collaboration, funding amount, trial design, and background on the drug and disease. There are no financial statements, regulatory certifications, or detailed financial results. The content is primarily an announcement of a capital funding event related to clinical trial financing. It does not contain financial performance data or detailed management discussion. Therefore, it fits best under Capital/Financing Update (CAP) as it updates on company fundraising and financing activities related to the clinical trial funding.
2022-08-31 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.